Topotecan combination chemotherapy in two new rodent models of retinoblastoma

Clinical Cancer Research

Volumn 11, Issue 20, 2005, Pages 7569-7578

  Laurie, Nikia A ^a   Gray, Jonathan K ^a   Zhang, Jiakun ^a   Leggas, Mark ^a   Relling, Mary ^a   Egorin, Merrill ^b   Stewart, Clinton ^a   Dyer, Michael A ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; ETOPOSIDE; GREEN FLUORESCENT PROTEIN; LUCIFERASE; TOPOTECAN; VINCRISTINE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CRYOTHERAPY; DRUG EFFICACY; E1A GENE; GENE; LC 50; LOW LEVEL LASER THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETINOBLASTOMA; SALVAGE THERAPY; SCREENING; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANIMALS, NEWBORN; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARBOPLATIN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ETOPOSIDE; EYE; HUMANS; MICE; MICE, KNOCKOUT; RATS; RETINAL NEOPLASMS; RETINOBLASTOMA; TIME FACTORS; TOPOTECAN; VINCRISTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 27144450572     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0849     Document Type: Article

References (45)

1. Dyer MA. Mouse models of childhood cancer of the nervous system. J Clin Pathol 2004;57:561-76.
2. Young J, Smith M, Roffers S, Liff J, Bunin G. Retinoblastoma. Bethesda: National Cancer Institute; 2003.
3. Gurney J, Smith M, Ross J. Cancer among infants. Bethesda: National Cancer Institute; 2003.
4. DiCiommo D, Gallie BL, Bremner R. Retinoblastoma: the disease, gene and protein provide critical leads to understand cancer. Semin Cancer Biol 2000;10:255-69.
5. Knudson A, Strong L. Mutations and cancer: neuroblastoma and pheochromocytomea. Am J Hum Genet 1972;24:514-22.
6. Rodriguez-Galindo C, Wilson MW, Haik BG, et al. Treatment of metastatic retinoblastoma. Ophthalmology 2003;110:1237-40.
7. Rodriguez-Galindo C, Wilson MW, Haik BG, et al. Treatment of intraocular retinoblastoma with vincristine and carboplatin. J Clin Oncol 2003;21:2019-25.
8. Nishimura S, Sato T, Ueda H, Ueda K. Acute myeloblastic leukemia as a second malignancy in a patient with hereditary retinoblastoma. J Clin Oncol 2001;19:4182-3.
9. Romer JT, Curran T. Medulloblastoma and retinoblastoma oncology recapitulates ontogeny. Cell Cycle 2004;3:917-9.
10. Romer JT, Kimura H, Magdaleno S, et al. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1+/-,p53-/-mice. Cancer Cell 2004;6:229-400.
11. del Cerro M, Seigel GM, Lazar E, et al. Transplantation of Y79 cells into rat eyes: an In vivo model of human retinoblastomas. Invest Ophthalmol Vis Sci 1993;34:3336-46.
12. Chevez-Barrios P, Hurwitz MY, Louie K, et al. Metastatic and nonmetastatic models of retinoblastoma. Am J Pathol 2000;157:1405-12.
13. O'Brien JM, Marcus DM, Bernards R, et al. A transgenic mouse model for trilateral retinoblastoma. Arch Ophthalmol 1990;108:1145-51.
14. Zhang J, Schweers B, Dyer MA. The first knockout mouse model of retinoblastoma. Cell Cycle 2004;3:952-9.
15. Chen D, Livne-Bar I, Vanderluit JL, Slack RS, Agochiya M, Bremner R. Cell-specific effects of RB or RB/p107 loss on retinal development implicate an intrinsically death-resistant cell-of-origin in retino-blastoma. Cancer Cell 2004;5:539-51.
16. MacPherson D, Sage J, Kim T, Ho D, McLaughlin ME, Jacks T. Cell type-specific effects of Rb deletion in the murine retina. Genes Dev 2004;18:1681-94.
17. Thompson J, Stewart CF, Houghton PJ. Animal models for studying the action of topoisomerase I targeted drugs. Biochim Biophys Acta 1998;1400:301-19.
18. Thompson J, George EO, Poquette CA, et al. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. Clin Cancer Res 1999;5:3617-31.
19. Houghton JA, Cook RL, Lutz PJ, Houghton PJ. Childhood rhabdomyosarcoma xenografts: responses to DNA-interacting agents and agents used in current clinical therapy. Eur J Cancer Clin Oncol 1984;20:955-60.
20. Houghton JA, Williams LG, Torrance PM, Houghton PJ. Determinants of intrinsic sensitivity to Vinca alkaloids in xenografts of pediatric rhabdomyosarcomas. Cancer Res 1984;44:582-90.
21. Gaynon PS, Ettinger LJ, Baum ES, Siegel SE, Krailo MD, Hammond GD. Carboplatin in childhood brain tumors. A Children's Cancer Study Group phase II trial. Cancer 1990;66:2465-9.
22. Allen JC, Walker R, Luks E, Jennings M, Barfoot S, Tan C. Carboplatin and recurrent childhood brain tumors. J Clin Oncol 1987;5:459-63.
23. McFall RC, Sery TW, Makadon M. Characterization of a new continuous cell line derived from a human retinoblastoma. Cancer Res 1977;37:1003-10.
24. Dyer MA, Cepko CL. p27Kip1 and p57Kip2 regulate proliferation in distinct retinal progenitor cell populations. J Neurosci 2001;21:4259-71.
25. Zhu CC, Dyer MA, Uchikawa M, Kondoh H, Lagutin OV, Oliver G. Six-3 mediated auto repression and eye development requires its interaction with members of the Grouch-related family of co-repressors. Development 2002;129:2835-49.
26. Dyer MA, Cepko CL. p57(Kip2) regulates progenitor cell proliferation and amacrine interneuron development in the mouse retina. Development 2000;127:3593-605.
27. Simpson AE, Gilbert JA, Rudnick DE, Geroski DH, Aaberg TM, Jr., Edelhauser HF. Transscleral diffusion of carboplatin: an in vitro and in vivo study. Arch Ophthalmol 2002;120:1069-74.
28. Cai X, Woo MH, Edick MJ, Relling MV. Simultaneous quantitation of etoposide and its catechol metabolite in human plasma using high-performance liquid chromatography with electrochemical detection. J Chromatogr 1999;728:241-50.
29. Schouten-Van Meeteren AY, Moll AC, Imhof SM, Veerman AJ. Overview: chemotherapy for retinoblastoma: an expanding area of clinical research. Med Pediatr Oncol 2002;38:428-38.
30. Dyer MA. Regulation of proliferation, cell fate specification and differentiation by the homeodomain proteins Prox1, Six3, and Chx10 in the developing retina. Cell Cycle 2003;2:350-7.
31. Dyer MA, Cepko CL. The p57(Kip2) cyclin kinase inhibitor is expressed by a restricted set of amacrine cells in the rodent retina. J Comp Neurol 2001;429:601-14.
32. Wang LG, Liu XM, Kreis W, Budman DR. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 1999;44:355-61.
33. Tonda ME, Murry DJ, Rodman JH. Formation of platinum-DNA adducts in pediatric patients receiving carboplatin. Pharmacotherapy 1996;16:631-7.
34. Peyman GA, Schulman JA. Intravitreal drug therapy. Jpn J Ophthalmol 1989;33:392-404.
35. Relling MV, Mahmoud HH, Pui CH et al. Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia. J Clin Oncol 1996;14:399-404.
36. Clancy B, Darlington RB, Finlay BL. Translating developmental time across mammalian species. Neuroscience 2001;105:7-17.
37. Zhang J, Gray J, Wu L, et al. Rb regulates proliferation and rod photoreceptor development in the mouse retina. Nat Genet 2004;36:351-60.
38. Chantada GL, Fandino AC, Casak SJ, Mato G, Manzitti J, Schvartzman E. Activity of topotecan in retinoblastoma. Ophthalmic Genet 2004;25:37-43.
39. Frangoul H, Ames MM, Mosher RB, et al. Phase I study of topotecan administered as a 21-day continuous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group. Clin Cancer Res 1999;5:3956-62.
40. Nitschke R, Parkhurst J, Sullivan J, Harris MB, Bernstein M, Pratt C. Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study. J Pediatr Hematol Oncol 1998;20:315-8.
41. Dyer MA, Bremner R. The search for the retinoblastoma cell of origin. Nat Rev Cancer 2005;5:91-101.
42. Houghton JA, Williams LG, Houghton PJ. Stability of vincristine complexes in cytosols derived from xenografts of human rhabdomyosarcoma and normal tissues of the mouse. Cancer Res 1985;45:3761-7.
43. Athale UH, Stewart C, Kuttesch JF, et al. Phase I study of combination topotecan and carboplatin in pediatric solid tumors. J Clin Oncol 2002;20:88-95.
44. Hayden BH, Murray TG, Scott IU, et al. Subconjunctival carboplatin in retinoblastoma: impact of tumor burden and dose schedule. Arch Ophthalmol 2000;118:1549-54.
45. Tubergen DG, Stewart CF, Pratt CB, et al. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study. J Pediatr Hematol Oncol 1996;18:352-61.